Clinical Workshop: Tumor Agnostic Approaches to Care
Tuesday, December 5 • 2:05 p.m. – 3:05 p.m. • Stars at Night Ballroom 1-2

Presentation: Antibody-Drug Conjugate Development Across Tumor Types

Joshua Z. Drago, MD, MS
Memorial Sloan Kettering Cancer Center,
New York, New York

What is your presentation about?
Antibody-drug conjugates (ADCs) are being rapidly developed as cancer therapies in multiple solid tumor types. In this talk I will discuss some of the successes and failures of ADCs from breast cancer and beyond. I will highlight the general principles that predict benefit from (or resistance to) ADCs and also distill lessons we can learn from other cancers that we can apply to improve outcomes for patients with breast cancer.

What makes this topic important in 2023?
In 2023, cancer treatment is evolving at a very rapid pace, and many clinicians and researchers are focused on their own specific cancer type. However, important lessons can be learned from experiences across the broad field of oncology. Breaking these silos is critically important for innovation and can result in important advances for patients living with cancer.